Novavax, Inc. (NVAX)
10.22
-0.12
(-1.16%)
USD |
NASDAQ |
Sep 04, 16:00
10.19
-0.03
(-0.29%)
After-Hours: 20:00
Novavax Research and Development Expense (Quarterly) : 67.79M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 67.79M |
| March 31, 2026 | 95.47M |
| December 31, 2025 | 73.98M |
| September 30, 2025 | 98.17M |
| June 30, 2025 | 77.63M |
| March 31, 2025 | 88.94M |
| December 31, 2024 | 104.28M |
| September 30, 2024 | 83.36M |
| June 30, 2024 | 106.65M |
| March 31, 2024 | 92.68M |
| December 31, 2023 | 164.70M |
| September 30, 2023 | 106.63M |
| June 30, 2023 | 216.78M |
| March 31, 2023 | 247.10M |
| December 31, 2022 | 257.85M |
| September 30, 2022 | 304.30M |
| June 30, 2022 | 289.65M |
| March 31, 2022 | 383.48M |
| December 31, 2021 | 962.96M |
| September 30, 2021 | 408.20M |
| June 30, 2021 | 570.68M |
| March 31, 2021 | 592.67M |
| December 31, 2020 | 401.20M |
| September 30, 2020 | 294.09M |
| June 30, 2020 | 34.85M |
| Date | Value |
|---|---|
| March 31, 2020 | 16.90M |
| December 31, 2019 | 29.34M |
| September 30, 2019 | 18.61M |
| June 30, 2019 | 30.42M |
| March 31, 2019 | 35.47M |
| December 31, 2018 | 43.42M |
| September 30, 2018 | 41.33M |
| June 30, 2018 | 44.54M |
| March 31, 2018 | 44.51M |
| December 31, 2017 | 49.66M |
| September 30, 2017 | 41.86M |
| June 30, 2017 | 39.26M |
| March 31, 2017 | 37.65M |
| December 31, 2016 | 51.10M |
| September 30, 2016 | 52.98M |
| June 30, 2016 | 64.90M |
| March 31, 2016 | 68.95M |
| December 31, 2015 | 75.90M |
| September 30, 2015 | 27.92M |
| June 30, 2015 | 25.04M |
| March 31, 2015 | 25.89M |
| December 31, 2014 | 30.50M |
| September 30, 2014 | 19.22M |
| June 30, 2014 | 15.20M |
| March 31, 2014 | 14.52M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Moderna, Inc. | 588.00M |
| Merck & Co., Inc. | 9.229B |
| Pfizer Inc. | 2.746B |
| Recursion Pharmaceuticals, Inc. | 77.91M |
| Agenus, Inc. | 14.76M |